Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII

Thrombosis Research

Volumn 131, Issue 1, 2013, Pages 78-88

  Kannicht, Christoph ^a   Ramström, Margareta ^b   Kohla, Guido ^a   Tiemeyer, Maya ^c   Casademunt, Elisabeth ^c   Walter, Olaf ^d   Sandberg, Helena ^b  

^a Octapharma RandD   (Germany)

^b Octapharma   (Sweden)

^c Octapharma   (Germany)

^d Octapharma   (Switzerland)

Author keywords

factor VIII inhibitors; Haemophilia A; HEK 293 F cell line; human cl rhFVIII; post translational modifications

Indexed keywords

EPITOPE; GALACTOSE; GLYCAN; MANNOSE; N GLYCOLOYLNEURAMINIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT HUMAN BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL LINE; CELL STRAIN BHK; CHO CELL; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; SULFATION;

ANIMALS; ANTIGENS; CHO CELLS; CHROMATOGRAPHY, ION EXCHANGE; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; FACTOR VIII; GLYCOSYLATION; HEK293 CELLS; HUMANS; MASS SPECTROMETRY; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; SULFATES; TRANSFECTION; TYROSINE;

EID: 84871660904     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.09.011     Document Type: Article

References (70)

1. A. Iorio, S. Halimeh, S. Holzhauer, N. Goldenberg, E. Marchesini, and M. Marcucci Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review J Thromb Haemost 8 2010 1256 1265
2. C. Brower, A.R. Thompson, and A. Hemophilia http://www.ncbi.nlm.nih.gov/ bookshelf/br.fcgi?book=gene&part=hemo-a accessed 30 Apr. 2010
3. P.M. Mannucci Hemophilia: treatment options in the twenty-first century J Thromb Haemost 1 2003 1349 1355
4. E. Berntorp, V. Boulyjenkov, D. Brettler, M. Chandy, P. Jones, and C. Lee Modern treatment of haemophilia Bull World Health Organ 73 1995 691 701 (Pubitemid 26020631)
5. E. Berntorp Progress in haemophilic care: ethical issues Haemophilia 8 2002 435 438 (Pubitemid 35277170)
6. E.G. Tuddenham, C. Kannicht, C. Agerkvist, H. Sandberg, S. Knaub, and N. Zozulya From human to humans - Introducing the first recombinant human FVIII product produced from a human line cell. A special symposium at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2009 Thromb Haemost 103 2010 [loose insert]
7. M. Brooker World Federation of Hemophilia: Registry of clotting factor concentrates 8th ed. 2011 www.wfh.org, accessed 2 Feb.
8. S.A. Brooks Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins Expert Rev Proteomics 3 2006 345 359 (Pubitemid 43979408)
9. G. Walsh, and R. Jefferis Post-translational modifications in the context of therapeutic proteins Nat Biotechnol 24 2006 1241 1252 (Pubitemid 44564769)
10. S. Bjorkman A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing Haemophilia 17 2011 179 184
11. C.H. Chung, B. Mirakhur, E. Chan, Q.T. Le, J. Berlin, and M. Morse Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose N Engl J Med 358 2008 1109 1117 (Pubitemid 351398485)
12. P.M. Mannucci Back to the future: a recent history of haemophilia treatment Haemophilia 14 Suppl. 3 2008 10 18 (Pubitemid 351722377)
13. A.F. Mohamed, J.D. Epstein, and J.M. Li-McLeod Patient and parent preferences for haemophilia A treatments Haemophilia 17 1-3-2011 209 214
14. W.C. Lee, A.V. Joshi, S. Woolford, M. Sumner, M. Brown, and N. Hadker Physicians' preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment Haemophilia 14 2008 454 465 (Pubitemid 351638731)
15. C.E. Ettingshausen, and W. Kreuz Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development Haemophilia 12 Suppl. 6 2006 102 106 (Pubitemid 44741510)
16. H.H. Brackmann, J. Oldenburg, and R. Schwaab Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'bonn protocol' Vox Sang 70 Suppl. 1 1996 30 35 (Pubitemid 26055992)
17. J. Astermark, M. Morado, A. Rocino, H.M. van den Berg, D.M. Von, and A. Gringeri Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors Haemophilia 12 2006 363 371
18. M.N. Di Minno, M.G. Di, C.M. Di, A.M. Cerbone, and A. Coppola Cost of care of haemophilia with inhibitors Haemophilia 16 2010 e190 e201
19. M.P. Kosloski, R.D. Miclea, and S.V. Balu-Iyer Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII AAPS J 11 2009 424 431
20. A. Leyte, H.B. Van Schijndel, C. Niehrs, W.B. Huttner, M.P. Verbeet, and K. Mertens Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor J Biol Chem 266 1991 740 746 (Pubitemid 21907177)
21. R.J. Sola, and K. Griebenow Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy BioDrugs 24 2010 9 21
22. S.A. Brooks Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system Mol Biotechnol 28 2004 241 255
23. J. Goudemand, C. Rothschild, V. Demiguel, C. Vinciguerrat, T. Lambert, and H. Chambost Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A Blood 107 2006 46 51 (Pubitemid 43054971)
24. J. Astermark Prevention and prediction of inhibitor risk Haemophilia 18 Suppl. 4 2012 38 42
25. R. Kruse-Jarres Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A Hematology Am Soc Hematol Educ Program 2011 2011 407 412
26. K.R. Viel, D.K. Machiah, D.M. Warren, M. Khachidze, A. Buil, and K. Fernstrom A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels Blood 109 2007 3713 3724 (Pubitemid 46641720)
27. L.M. Aledort, R.J. Navickis, and M.M. Wilkes Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies J Thromb Haemost 9 2011 2180 2192
28. A. Iorio, M. Marcucci, and M. Makris Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost 9 2011 2176 2179
29. M. Makris, G. Calizzani, K. Fischer, E.A. Gilman, C.R. Hay, and R. Lassila EUHASS: The European Haemophilia Safety Surveillance system Thromb Res 127 Suppl. 2 2011 S22 S25
30. J. Goudemand Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates Haemophilia 13 Suppl. 5 2007 47 51 (Pubitemid 350253404)
31. W. Kreuz The role of VWF for the success of immune tolerance induction Thromb Res 122 Suppl. 2 2008 S7 S12
32. W. Kreuz, and C.E. Ettinghausen ObsITI Study http://www.obsiti.com/ accessed 2 Feb. 2011
33. S. Delignat, S. Dasgupta, S. Andre, A.M. Navarrete, S.V. Kaveri, and J. Bayry Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A Haematologica 92 2007 1423 1426 (Pubitemid 350144163)
34. Y. Lin, X. Yang, M.C. Chevrier, S. Craven, T.W. Barrowcliffe, and R. Lemieux Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates Haemophilia 10 2004 459 469 (Pubitemid 39317754)
35. A. Klukowska, V. Komrska, M. Jansen, and P. Laguna Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study Haemophilia 17 1-12-2010 399 406
36. F. Altmann, E. Staudacher, I.B.H. Wilson, and L. März Insect cells as hosts for the expression of recombinant glycoproteins Glycoconj J 16 1999 109 123 (Pubitemid 29472137)
37. F.R. Schmidt Recombinant expression systems in the pharmaceutical industry Appl Microbiol Biotechnol 65 2004 363 372 (Pubitemid 39281088)
38. S.W. Pipe The promise and challenges of bioengineered recombinant clotting factors J Thromb Haemost 3 2005 1692 1701 (Pubitemid 41716555)
39. R.G. Werner, W. Noé, K. Kopp, and M. Schlütter Appropriate mammalian expression systems for biopharmaceuticals Arzneim -Forsch /Drug Res 48 II 1998 870 880 (Pubitemid 28395153)
40. W.F. Schilow, E. Schoerner-Burkhardt, and R. Seitz Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards Thromb Haemost 92 2004 427 428 (Pubitemid 39172325)
41. N. Sethuraman, and T.A. Stadheim Challenges in therapeutic glycoprotein production Curr Opin Biotechnol 17 2006 341 346 (Pubitemid 44163459)
42. E. Casademunt, K. Martinelle, M. Jernberg, S. Winge, M. Tiemeyer, and L. Biesert The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics Eur J Haematol 89 2012 165 176
43. D. Jones, N. Kroos, and R. Anema van MB, Vooys A, van der Kraats S et al. High-level expression of recombinant IgG in the human cell line per.c6 Biotechnol Prog 19 2003 163 168 (Pubitemid 36219317)
44. A.D. Shapiro, M.V. Ragni, L.A. Valentino, N.S. Key, N.C. Josephson, and J.S. Powell Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients Blood 119 2012 666 672
45. H. Sandberg, A. Almstedt, J. Brandt, V.M. Castro, E. Gray, and L. Holmquist Structural and functional characterization of B-domain deleted recombinant factor VIII Semin Hematol 38 2001 4 12 (Pubitemid 32612094)
46. C. Gronwall, A. Sjoberg, M. Ramstrom, I. Hoiden-Guthenberg, S. Hober, and P. Jonasson Affibody-mediated transferrin depletion for proteomics applications Biotechnol J 2 2007 1389 1398 (Pubitemid 350162260)
47. M. Ramstrom, and H. Sandberg Characterization of gamma-carboxylated tryptic peptides by collision-induced dissociation and electron transfer dissociation mass spectrometry Eur J Mass Spectrom 17 2011 497 506
48. M. Ramström, U. Eriksson, H. Sandberg. Mass Spectrometry-Based Strategies for Characterization of N-glycosylation Sites of Human Coagulation Factor VIII Functional Domains. 18th International Mass Spectrometry Conference 2009, Bremen, Germany.
49. T.R. Cataldi, C. Campa, and G.E. De Benedetto Carbohydrate analysis by high-performance anion-exchange chromatography with pulsed amperometric detection: the potential is still growing Fresenius J Anal Chem 368 2000 739 758
50. T. Hironaka, K. Furukawa, P.C. Esmon, M.A. Fournel, S. Sawada, and M. Kato Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells J Biol Chem 267 1992 8012 8020
51. B.W. Shen, P.C. Spiegel, C.H. Chang, J.W. Huh, J.S. Lee, and J. Kim The tertiary structure and domain organization of coagulation factor VIII Blood 111 2008 1240 1247 (Pubitemid 351213406)
52. P.J. Lenting, O.D. Christophe, and P. Gueguen The disappearing act of factor VIII Haemophilia 2008 1 10
53. S.W. Pipe Functional roles of the factor VIII B domain Haemophilia 15 2009 1187 1196
54. L. Thim, B. Vandahl, J. Karlsson, N.K. Klausen, J. Pedersen, and T.N. Krogh Purification and characterization of a new recombinant factor VIII (N8) Haemophilia 16 2010 349 359
55. N. Bihoreau, J.F. Veillon, C. Ramon, J.M. Scohyers, and J.M. Schmitter Characterization of a recombinant antihaemophilia-A factor (Factor VIII-deltaII) by matrix-assisted laser desorption/ionization mass spectrometry Rapid Commun Mass Spectrom 9 1995 1584 1588
56. P. Lollar, D.C. Hill-Eubanks, and C.G. Parker Association of the factor VIII light chain with von Willebrand factor J Biol Chem 263 1988 10451 10455
57. J. Mikkelsen, J. Thomsen, and M. Ezban Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII Biochemistry 30 1991 1533 1537
58. M. Kjalke, A. Heding, G. Talbo, E. Persson, J. Thomsen, and M. Ezban Amino acid residues 721-729 are required for full factor VIII activity Eur J Biochem 234 1995 773 779 (Pubitemid 26023430)
59. R.J. Kaufman Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology Ann Hematol 63 1991 155 165
60. A.A. Bergwerff, and J.E. Thomas-Oates van OJ, Kamerling JP, Vliegenthart JF. Human urokinase contains GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2) as a novel terminal element in N-linked carbohydrate chains FEBS Lett 314 1992 389 394 (Pubitemid 23005696)
61. A. Dell, H.R. Morris, R.L. Easton, M. Panico, M. Patankar, and S. Oehniger Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities J Biol Chem 270 1995 24116 24126
62. S.B. Yan, and Y.B. Chao van HH. Novel Asn-linked oligosaccharides terminating in GalNAc beta (1->4)[Fuc alpha (1->3)]GlcNAc beta (1->.) are present in recombinant human protein C expressed in human kidney 293 cells Glycobiology 3 1993 597 608 (Pubitemid 24028867)
63. B.W. Grinnell, R.B. Hermann, and S.B. Yan Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide Glycobiology 4 1994 221 225 (Pubitemid 24147897)
64. B.A. Macher, and U. Galili The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance Biochim Biophys Acta 1780 2008 75 88
65. S.L. Diaz, V. Padler-Karavani, D. Ghaderi, N. Hurtado-Ziola, H. Yu, and X. Chen Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products PLoS One 4 2009 e4241
66. U. Galili Xenotransplantation and ABO incompatible transplantation: the similarities they share Transfus Apher Sci 35 2006 45 58 (Pubitemid 44354321)
67. D.C. LaTemple, J.T. Abrams, S.Y. Zhang, and U. Galili Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase Cancer Res 59 1999 3417 3423 (Pubitemid 29334502)
68. K. Yamashita, T. Ohkura, Y. Tachibana, S. Takasaki, and A. Kobata Comparative study of the oligosaccharides released from baby hamster kidney cells and their polyoma transformant by hydrazinolysis J Biol Chem 259 1984 10834 10840 (Pubitemid 14031211)
69. H.P. Kumar, C. Hague, T. Haley, C.M. Starr, M.J. Besman, and R.L. Lundblad Elucidation of N-linked oligosaccharide structures of recombinant human factor VIII using fluorophore-assisted carbohydrate electrophoresis Biotechnol Appl Biochem 24 Pt 3 1996 207 216 (Pubitemid 26414179)
70. A. Bohne-Lang, and C.W. von der Lieth GlyProt: in silico glycosylation of proteins Nucleic Acids Res 33 2005 W214 W219 (Pubitemid 44529911)